Holen Sie sich die Stockscreener-App
3.855
5.60%
-0.215
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.5%What's Next? - MarketBeat
Iovance Biotherapeutics at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum - Sahm
Iovance Biotherapeutics (IOVA) Is Up 42.7% After Positive Lifileucel Sarcoma Data And New Trial Plan - Sahm
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD - Investing.com Nigeria
Iovance Biotherapeutics Shines with TIL Therapy Success and Financial Gain - timothysykes.com
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus - Yahoo Finance
Is It Too Late To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Sahm
Iovance (IOVA) Soars 33%, Hits All-Time High - Insider Monkey
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target - Finviz
Iovance (IOVA) hits 52-week high as analyst doubles price target - MSN
Momentum Shift: Is Iovance Biotherapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Naître et grandir
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum - International Business Times Australia
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum - Quiver Quantitative
Iovance Biotherapeutics Expands Clinical Trials Amid Strategic Upgrades - timothysykes.com
What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
Iovance Biotherapeutics Shines with Positive Trial Outcomes and Upgraded Ratings - StocksToTrade
UBS Raises PT on Iovance Biotherapeutics (IOVA) - Insider Monkey
Iovance Biotherapeutics stock hits 52-week high at 4.35 USD By Investing.com - Investing.com Canada
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - Yahoo Finance
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - The Motley Fool
Key facts: Iovance Biotherapeutics expands TIL therapy; UBS raises price target - TradingView
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $4.00 at UBS Group - MarketBeat
UBS Adjusts Iovance Biotherapeutics Price Target to $4 From $2, Maintains Neutral Rating - marketscreener.com
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat
A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - simplywall.st
Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance
IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Potential Upside of 132% Amid Rising Investor Interest - DirectorsTalk Interviews
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance
Iovance (NASDAQ: IOVA) CCO vests 120,000 PSUs, withholds shares for tax - Stock Titan
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success - Yahoo Finance
Strategic Milestones Propel Iovance Biotherapeutics Inc. - StocksToTrade
Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewswire
Brokers Set Expectations for IOVA Q1 Earnings - MarketBeat
Guidance Update: Whats the beta of Iovance Biotherapeutics Inc stockQuarterly Profit Report & Smart Swing Trading Techniques - baoquankhu1.vn
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - AOL.com
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress - The Globe and Mail
Iovance Highlights Amtagvi Revenue Growth and Profitability Path - The Globe and Mail
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):